Delivery Order SPE2DB22D1106-SPE2DB25FEYN4
- Not listed
- The Defense Logistics Agency awarded a $120,192.80 delivery order to AmerisourceBergen Drug Corp on July 24, 2025, for the supply of Ocrevus 300 mg/10 mL vials. This is a firm fixed-price contract with an ultimate completion date of August 14, 2025, and will be performed at the awardee's corporate office location in Conshohocken, Pennsylvania. The contract was competitively awarded with no set-aside designation, reflecting the contractor's demonstrated capability to meet federal pharmaceutical...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 12, 2025, for the supply of Ocrevus 300 mg/10 mL vials, a pharmaceutical product used to treat multiple sclerosis. This firm fixed-price delivery order, valued at $64,452.33, is scheduled for completion by September 3, 2025, with performance at AmerisourceBergen's Conshohocken, Pennsylvania facility. The contract was awarded without a set-aside designation through competitive procurement, reflecting...
- The Defense Logistics Agency (DLA) awarded a delivery order to AmerisourceBergen Drug Corp for the supply of Ocrevus 300 mg/10 ml vials with a ceiling value of $72,115.74. The contract, which was competitively awarded with no set-aside designation, carries a firm fixed price structure and is scheduled for completion by August 21, 2025. Performance will be executed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order operates under...
- The Defense Logistics Agency (DLA) awarded a delivery order contract to AmerisourceBergen Drug Corporation's Corporate Office division to provide Ocrevus 300 mg/10 ml vials. The fixed-price contract, valued at $69,354.24, has a completion date of June 6, 2024. This award is part of a larger Indefinite Delivery Contract (IDC) between AmerisourceBergen and DLA Troop Support Medical, valued up to $999,999,999.00 through December 31, 2025. The IDC serves as the primary vehicle for...
- This is a delivery order awarded by the Defense Logistics Agency (DLA) Troop Support Medical to AmerisourceBergen Drug Corporation, a major pharmaceutical distributor, for the supply of OCREVUS 300 mg/10 ml vials. The contract has a ceiling value of $69,354.24 and a completion date of August 9, 2024. It is a firm fixed-price delivery order contract, with no set-aside designation. AmerisourceBergen holds a significant Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, valued...
- The Defense Logistics Agency (DLA) awarded a firm fixed price delivery order contract worth $115,590.40 to Amerisourcebergen Drug Corp, a subsidiary of Amerisourcebergen Corporation, to provide OCREVUS 300 mg/10 ml vials with a completion date of March 20, 2024. This contract is part of a larger indefinite delivery contract (IDC) awarded solely to Amerisourcebergen Drug Corp by DLA, with a potential value of $999,999,999.00 and a performance period through December 31, 2025. The IDC serves as...
- The U.S. Defense Logistics Agency Troop Support Medical has awarded a $115,590.40 firm fixed price delivery order contract to Amerisourcebergen Drug Corp, a subsidiary of Amerisourcebergen Corporation, for the supply of OCREVUS 300 MG/10 ML VIAL 10ML. This delivery order is part of a larger indefinite delivery contract (IDC) awarded solely to Amerisourcebergen Drug Corp by DLA, with a potential value of $999,999,999.00 and a performance period through December 31, 2025. The IDC serves as the...
- The Defense Logistics Agency (DLA) Troop Support Medical awarded a $69,354.24 firm fixed price delivery order contract to AmerisourceBergen Drug Corp, a subsidiary of AmerisourceBergen Corporation. The contract is for the supply of OCREVUS 300 mg/10 ml vials, a specialty pharmaceutical product, to support military treatment programs and facilities. This order is part of a larger indefinite delivery contract (IDC) worth up to $999,999,999.00 awarded solely to AmerisourceBergen Drug Corp by DLA....
- This is a federal contract award issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract is a delivery order with a firm fixed price of $48,077.16 and a period of performance through May 14, 2025. The contract provides for the delivery of OCREVUS 300 MG/10 ML VIAL 10ML, a specialty pharmaceutical product. This contract is not set-aside and was competitively awarded. AmerisourceBergen Drug Corp...
- This federal contract award to AmerisourceBergen Drug Corp Corporate Office Division is a delivery order valued at $57,795.20 for the supply of OCREVUS 300 MG/10 ML VIAL 10ML. The contract is a firm fixed-price agreement with the Defense Logistics Agency (DLA), a defense agency. The contract has an ultimate completion date of September 3, 2024. AmerisourceBergen, a major pharmaceutical distributor, is the prime contractor for this award, which is not set aside for any specific business type....
- SPE2DB22D1106Indefinite Delivery Contract
- SPE2DB22D1106-SPE2DB25FEYN4Delivery Order
The Defense Logistics Agency awarded a delivery order valued at $36,057.84 to AmerisourceBergen Drug Corp on July 18, 2025, for the supply of Ocrevus 300 mg/10 mL vials. This firm fixed-price, non-set-aside contract is scheduled for completion by August 8, 2025, with performance at the contractor's location in Conshohocken, Pennsylvania. AmerisourceBergen, a major pharmaceutical distributor and critical vendor for federal medical procurement, will fulfill this order as part of its ongoing support for military and federal healthcare systems. This delivery order is issued under AmerisourceBergen's prime Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, valued at $999,999,999.00 and extending through December 2026. The SPE2DX vehicle serves as a comprehensive global pharmaceutical support contract enabling the company to supply a broad range of pharmaceutical products and medical supplies to support military healthcare programs worldwide. As a competitively awarded contractor under this framework, AmerisourceBergen demonstrates capability to meet federal pharmaceutical procurement requirements across multiple therapeutic domains.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $36.1k | 7/18/25 |